A Phase II Study of Poziotinib in EGFR Exon 20 Mutant Advanced Non-Small Cell Lung Cancer (NSCLC)
Phase of Trial: Phase II
Latest Information Update: 26 Jul 2017
At a glance
- Drugs Poziotinib (Primary)
- Indications Non-small cell lung cancer
- Focus Adverse reactions; Therapeutic Use
- 20 Jul 2017 Planned number of patients changed from 30 to 60.
- 02 May 2017 According to a Spectrum Pharmaceuticals media release, Interim results are expected before end of 2017.
- 20 Mar 2017 Planned End Date changed from 1 Apr 2021 to 1 Mar 2021.